NDA 020639 · Cheplapharm
Seroquel
Quetiapine Fumarate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Sep 26, 1997
Approved uses
8
Original approval plus efficacy supplements
Registered trials
398
129 Phase 3, 13 recruiting
FAERS reports
157,490
125,741 serious, 22,048 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death [see Warnings and Precautions (5.1) ] . SEROQUEL is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older [see Warnings and Precautions (5.2) ]. In...
What it is approved for
From the label in effect Apr 10, 2026.
SEROQUEL is an atypical antipsychotic indicated for the treatment of: • Schizophrenia ( 1.1 ) • Bipolar I disorder manic episodes (1.2) • Bipolar disorder, depressive episodes (1.2) 1.1 Schizophrenia SEROQUEL is indicated for the treatment of schizophrenia. The efficacy of SEROQUEL in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13-17 years). The effectiveness of SEROQUEL for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials [see Clinical Studies (14.1) ]. 1.2 Bipolar Disorder SEROQUEL is indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10-17 years) [see Clinical Studies (14.2) ]. SEROQUEL is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. Efficacy was established in two 8-week monotherapy trials in adult patients with bipolar I and bipolar II disorder [see Clinical Studies (14.2) ]. SEROQUEL is indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of SEROQUEL as monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials [see Clinical Studies (14.2) ]. 1.3 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis...
Mechanism: The mechanism of action of quetiapine in the listed indications is unclear. However, the efficacy of quetiapine in these indications could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2 (5HT 2 ) antagonism. The active metabolite, N-desalkyl quetiapine (norquetiapine), has similar activity at D 2 , but greater activity at 5HT 2A receptors, than the parent drug (quetiapine).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 30, 2013 Supplement 57 · Efficacy LabelPediatric CDTL ReviewPediatric Medical Review
- Dec 2, 2009 Supplement 46 · Efficacy · priority review LabelReviewLetter
- Dec 2, 2009 Supplement 45 · Efficacy · priority review Pediatric Statistical ReviewPediatric Medical ReviewPediatric CDTL Review
- May 13, 2008 Supplement 37 · Efficacy ReviewLabelLetter
- Oct 20, 2006 Supplement 26 · Efficacy LabelLetter
- Jan 12, 2004 Supplement 16 · Efficacy ReviewLabelLetter
- Jan 12, 2004 Supplement 17 · Efficacy ReviewLetterLabel
- Sep 26, 1997 Original approval · Type 1 - New Molecular Entity ReviewOtherPediatric Written Request
7 products under this application
- SEROQUEL · QUETIAPINE FUMARATE EQ 50MG BASE · TABLET, ORAL · Prescription · TE AB
- SEROQUEL · QUETIAPINE FUMARATE EQ 300MG BASE · TABLET, ORAL · Prescription · TE AB
- SEROQUEL · QUETIAPINE FUMARATE EQ 200MG BASE · TABLET, ORAL · Prescription · TE AB
- SEROQUEL · QUETIAPINE FUMARATE EQ 25MG BASE · TABLET, ORAL · Prescription · TE AB
- SEROQUEL · QUETIAPINE FUMARATE EQ 400MG BASE · TABLET, ORAL · Prescription · TE AB
- SEROQUEL · QUETIAPINE FUMARATE EQ 150MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued
- SEROQUEL · QUETIAPINE FUMARATE EQ 100MG BASE · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Quetiapine" as an intervention, any sponsor and status, largest first.
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT05480150 · 10,000 participants (planned) · Start Nov 1, 2021 · Primary completion Dec 31, 2026
Drug: Escitalopram Oxalate Tablets; Quetiapine Fumarate Tablets and 1 more · For: Major Depressive Disorder; Bipolar Disorder, Mixed; Affective; Disorder, Organic
Sites: Hangzhou, China
- Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive DisorderPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00278941 · 3,000 participants · Start Dec 2005
Drug: Quetiapine Fumarate Sustained Release · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Mesa, Arizona · 168 sites in all
- Sequential Multiple Assignment Randomized Trial for Bipolar DepressionPivotal-lookingActive, not recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06433635 · 2,726 participants (planned) · Start Oct 1, 2024 · Primary completion Feb 28, 2030
Drug: Cariprazine; Aripiprazole/Escitalopram combination and 2 more · For: Bipolar I Disorder; Depression
Sites: Birmingham, Alabama; Bloomington, Indiana; Baltimore, Maryland · 18 sites in all
- A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus TrialPivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01727726 · 2,182 participants · Start Dec 2012 · Primary completion Oct 17, 2016
Drug: Brexpiprazole; Seroquel XR and 1 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 76 sites in all
- Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major DepressionPivotal-lookingCompleted
University of SaskatchewanAcademic, hospital or other
NCT03207438 · 1,790 participants · Start Apr 2006 · Primary completion Jul 2007
Drug: Quetiapine 50 MG Extended Release Oral Tablet; Quetiapine Fumarate XR 150-300 mg and 1 more · For: Depressive Disorder, Major
- CATIE- Schizophrenia TrialPivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00014001 · 1,600 participants · Start Dec 2000
Drug: perphenazine; olanzapine and 5 more · For: Schizophrenia
Sites: Chula Vista, California; Los Angeles, California; Orange, California · 54 sites in all
- Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With SchizophreniaPivotal-lookingCompleted
Central South UniversityAcademic, hospital or other
NCT00654576 · 1,400 participants (planned) · Start Feb 2005 · Primary completion Dec 2007
Drug: Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole · For: Schizophrenia
Sites: Changsha, China
- Quetiapine Fumarate Bipolar Maintenance MonotherapyPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00314184 · 1,255 participants · Start Mar 2005
Drug: quetiapine fumarate · For: Bipolar Disorder
Sites: Cerritos, California; San Diego, California; Santa Ana, California · 95 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective9,492
- off label use9,102
- toxicity to various agents8,281
- diabetes mellitus7,992
- insomnia7,269
- somnolence6,823
- drug interaction6,691
- fatigue6,643
- nausea6,296
- anxiety6,218
- weight increased6,164
- depression5,996
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,549 |
| 2005 | 1,921 |
| 2006 | 3,134 |
| 2007 | 5,526 |
| 2008 | 3,245 |
| 2009 | 7,250 |
| 2010 | 7,817 |
| 2011 | 8,248 |
| 2012 | 8,422 |
| 2013 | 4,100 |
| 2014 | 5,067 |
| 2015 | 6,662 |
| 2016 | 6,646 |
| 2017 | 8,242 |
| 2018 | 9,649 |
| 2019 | 9,933 |
| 2020 | 10,079 |
| 2021 | 9,051 |
| 2022 | 8,575 |
| 2023 | 8,805 |
| 2024 | 8,863 |
| 2025 | 8,363 |
| 2026 | 6,339 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Seroquel (Quetiapine Fumarate)
2024 spending
$8.7M
Beneficiaries
1,904
11,938 claims
Per beneficiary
$4,568
$10.28 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $12,952,261 |
| 2021 | $11,504,475 |
| 2022 | $10,635,009 |
| 2023 | $9,868,368 |
| 2024 | $8,697,238 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Augmentation strategies for treatment resistant major depression: A systematic review and network meta-analysis.
Nuñez NA, Joseph B, Pahwa M, et al. · J Affect Disord 2022 · Network Meta-Analysis, Research Support, N.I.H., Extramural
- Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2021 · Network Meta-Analysis, Research Support, Non-U.S. Gov't
- Effects of quetiapine on sleep: A systematic review and meta-analysis of clinical trials.
Lin CY, Chiang CH, Tseng MM, et al. · Eur Neuropsychopharmacol 2023 · Meta-Analysis, Systematic Review
- Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.
Reif A, Bitter I, Buyze J, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Comparative Study
- Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis.
Yildiz A, Siafis S, Mavridis D, et al. · Lancet Psychiatry 2023 · Systematic Review, Network Meta-Analysis
Sponsor: Cheplapharm
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.